Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II pharmacokinetic and safety study of LF111 (drospirenone) in healthy Japanese women
jRCT2071200065Phase 2Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of drospirenone in contraception, sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoints: Pharmacokinetics of drospirenone after single dose, Pharmacokinetics of drospirenone at steady state after repeated doses and 2 more. Started Jan 2021; status: completed.
02
Drugs
drospirenone
03
Conditions
contraception
Beyond the preview
Go deeper on jRCT2071200065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200065.